Why Pharma Commercial Teams Have a Data Problem – Not an Analytics Problem

Every commercial leader I talk to at major industry events, whether it is the DIA Annual Meeting in Washington D.C., BIO International Convention in Boston, or ISPOR’s global conference, tells me the same story. They have more data than ever. Dashboards everywhere. And yet, when it comes to answering the questions that actually matter- which channel combination is moving prescribing, which territories are underperforming and why, how medical affairs engagement is influencing commercial outcomes ,  the answer is usually spreadsheets, gut feel, and a follow-up meeting that ends with someone agreeing to pull data offline.

That is not an analytics problem. That is a connectivity problem. And until pharma commercial leadership frames it that way, no amount of new tooling is going to fix it.

The Real Issue: Disconnected Intelligence

The average top 20 pharma company invests more than $200 billion annually on US commercial operations. A significant portion of that spend is allocated based on intuition dressed up as analysis – because the data that would enable genuine precision sits in separate systems, governed by separate teams, measured by separate KPIs designed for each function in isolation, never for the enterprise as a whole.

Your field force has CRM data in Veeva. Marketing tracks digital engagement in Marketo or Salesforce Marketing Cloud. Medical affairs logs HCP interaction records in a different platform. Market access tracks payer coverage in yet another tool. Patient services runs hub operations in a system that was never designed to talk to any of the above. Each function optimizes locally. The company sub-optimizes globally. This is what we call the Commercial Intelligence Deficit – and it costs the industry far more than most leaders are actually measuring.

Fewer than 11% of pharma organizations have achieved enterprise-wide AI deployment, despite years of strategy documents and significant pilot investment. The barrier is almost never the AI itself. It is the disconnected data foundation the AI is supposed to sit on.

What Connected Intelligence Actually Looks Like in Practice

At Infocepts, we have spent 21+ years building what we call a commercial intelligence layer – a governed data and AI architecture that sits across all commercial functions and creates shared context. Not another dashboard. The connective tissue that makes all your existing investments smarter, faster, and genuinely useful to the people who need to act on them.

Here is what that looks like in the real world. A global biotech client was making territory call-planning decisions based on Veeva CRM activity data alone. Prescribing decile determined call frequency. When we connected their digital engagement data – webinar attendance, email open patterns, medical portal logins, congress registrations – with their CRM activity and prescription data into a unified Snowflake-based platform, we found that HCPs with at least two digital touchpoints before a rep visit prescribed at 2.3 times the rate of HCPs who received cold rep contact only. The field team restructured call planning immediately. Year-1 sales increased 20% across 30+ countries. That outcome did not come from a better AI model. It came from connecting data that was already being collected but had never been joined at the HCP level.

Why Most Pharma Analytics Programs Stall

Three barriers consistently prevent pharma organizations from reaching true commercial intelligence maturity. These are not hypothetical – they are what we encounter at the start of nearly every engagement.

• Point-solution thinking: Every function buys the tool that solves its immediate problem. The result is 20+ disconnected tools, none designed to talk to the others. Over time, maintaining that fragmented stack consumes more engineering capacity than the analytics work that would actually move the business.
• Governance gaps: In a regulated industry, data without documented lineage, role-based access, and automated quality monitoring is a compliance risk, not just an analytics problem. Most programs treat governance as something to add at the end of a build. By then, it is retrofitted rather than designed – expensive, incomplete, and frequently inadequate for regulatory scrutiny.
• Operationalization failure: Models get built and sit on shelves. Dashboards go unused after the first month. The gap between a working prototype and a system that 800 field representatives use every day is enormous – and it is a people and process gap, not a technology gap. Most analytics programs dramatically underinvest in change management, adoption strategy, and the feedback loops that keep a system relevant.

The Infocepts Commercial Intelligence Model

We are not a BI vendor. We are not staff augmentation. Every engagement we run is tied to measurable business KPIs from day one – sales increase, rep productivity improvement, adherence rate gain, patient enrollment acceleration. GxP, HIPAA, and GDPR compliance is built into the architecture from the first design conversation, not retrofitted. Operationalization is a formal deliverable in every engagement, not an afterthought.

Our 97.2% client retention rate and three consecutive years as the highest-rated provider on Gartner Peer Insights reflect what happens when analytics investments are tied to outcomes that business leaders care about rather than technical deliverables that IT can check off. Partnerships that last 7+ years, not projects that close and disappear.

The Commercial Intelligence Diagnostic

If your commercial analytics roadmap still looks like a collection of function-specific tool upgrades heading into your next planning cycle, you are solving the wrong problem. The right starting point is a diagnostic: map where your commercial data lives, who owns it, what definitions conflict across teams, and where the decision points are that no current system can answer.

That diagnostic almost always surfaces three to four high-value connection opportunities – places where linking data across two or three existing systems would unlock a business insight that is currently unavailable and directly actionable. Those are the places where analytics investment pays off fastest because the return is concrete and the stakeholders are ready to move.

Three Questions Worth Answering This Quarter

Can your commercial leadership team tell you, without pulling data manually,  what the prescribing impact is of combining a rep visit with a prior digital touchpoint? Can your medical affairs leadership see how MSL engagement with KOLs influences downstream prescribing in surrounding geographies? Can your market access team give field reps real-time payer coverage data at the account level before a sales call?

If the answer to any of these is no, you have identified a commercial intelligence gap that is costing real money. You have also identified the starting point for an analytics investment that can show measurable ROI within a single quarter. That is where we work. And that is where the real value in commercial data investment lives.

The pharma companies that win the next decade of commercial competition will not be the ones with the most dashboards. They will be the ones with a single, connected, governed view of their customer – and the operational systems to act on it in real time. Building that view is not a multi-year aspiration. It is a decision made in a planning cycle. That decision is available to you right now.